Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
주식 순위 #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
주가
$0.12164306
마지막 동기화: 2024-11-11
시가총액
$38.53M
변동 (1일)
-4.14%
변동 (1년)
0.00%
국가
AU
거래 PharmAust Limited (PAA)

카테고리

PharmAust Limited (PAA)의 매출
Jun 2024 기준 매출 TTM: $572.45K
PharmAust Limited의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $572.45K입니다. 2023년에 회사는 $1.88M의 수익을 올렸으며 이는 2022년의 $2.33M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
PharmAust Limited의 수익 기록 (2001 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $572.45K 0.00%
2024 0.00 -100.00%
2023 $1.88M -19.32%
2022 $2.33M 45.33%
2021 $1.60M -27.22%
2020 $2.21M -27.76%
2019 $3.05M 26.47%
2018 $2.41M -5.23%
2017 $2.55M 25.80%
2016 $2.02M 10.90%
2015 $1.83M -0.20%
2014 $1.83M 17.05%
2013 $1.56M -5.48%
2012 $1.65M -0.67%
2011 $1.66M 19.79%
2010 $1.39M -2.17%
2009 $1.42M -47.01%
2008 $2.68M -55.73%
2007 $6.05M 33.53%
2006 $4.53M 85.63%
2005 $2.44M 1,047.74%
2004 $212.83K 366.98%
2003 $45.58K -88.07%
2002 $381.98K 0.00%
2001 0.00 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B 2,205,224.96%
US
$6.02B 1,051,752.00%
NL
$15.70B 2,741,683.32%
AU
$2.23B 389,106.85%
US
- -
CH